Test Code HV2QU HIV-2 RNA Detection and Quantification, Real-Time qRT-PCR, Plasma
Ordering Guidance
This test is indicated for either 1) confirmatory qualitative detection of HIV-2 RNA in individuals with indeterminate or positive HIV-2-specific antibody but negative HIV-1-specific antibody test results; or 2) baseline or serial monitoring of HIV-2 viral load in those with confirmed HIV-2 infection with or without antiretroviral therapy.
Shipping Instructions
Ship specimen frozen on dry ice. If shipment will be delayed for more than 24 hours, freeze specimen at -20 to -80° C (up to 35 days) before shipment and then transport on dry ice.
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 2.1 mL Plasma
Collection Instructions: Centrifuge and aliquot plasma into a plastic vial.
Useful For
Confirmatory detection of human immunodeficiency virus type 2 (HIV-2) RNA in clinical plasma specimens for the diagnosis of acute or established HIV-2 infection
Quantifying plasma HIV-2 RNA levels (viral load) in individuals living with HIV-2:
-Before initiating antiretroviral therapy to obtain baseline viral load
-For monitoring HIV-2 disease progression with or without antiretroviral therapy
Testing Algorithm
The following algorithms are available:
-HIV Prenatal Testing Algorithm, Including Follow-up of Reactive Rapid Serologic Test Results
Special Instructions
Method Name
Reverse Transcription Real-time Polymerase Chain Reaction (RT-qPCR)
Reporting Name
HIV-2 RNA Detect / Quant, PSpecimen Type
Plasma EDTASpecimen Minimum Volume
Plasma: 1.1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma EDTA | Frozen (preferred) | 60 days | ALIQUOT TUBE |
| Refrigerated | 6 days | ALIQUOT TUBE |
Reject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Clinical Information
Human immunodeficiency virus type 2 (HIV-2) is a lentivirus, a retrovirus in the same genus (Lentiviridae) as HIV-1. It was first isolated in 1986 in West Africa, where it is currently endemic. Most of these cases in the United States have been found in the northeastern United States, and the majority had a West African origin or connection.
Compared to HIV-1 infection, HIV-2 infection is associated with slower rate of progression, low viral load (which may not be reliably measured with current methods), slower rates of decline in CD4 cell count, and lower rates of transmission (sexually or vertically). Up to 95% of HIV-2-infected individuals are long-term non-progressors, and individuals with undetectable HIV-2 viral load have similar survival rates as that of the uninfected population. However, HIV-2 does cause immunosuppression as well as AIDS with the same signs, symptoms, and opportunistic infections seen in HIV-1. Due to the rarity of HIV-2, there are scant data from controlled trials to inform management decisions.
Reference Values
Undetected
Day(s) Performed
Varies (once per week)
Report Available
1 to 14 daysSpecimen Retention Time
60 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87539
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HV2QU | HIV-2 RNA Detect / Quant, P | 69354-9 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 623478 | HIV-2 RNA Detect / Quant, P | 69354-9 |